1. France Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - General
Sanofi

Sanofi

SNY.TO
SanofiCA flagToronto Stock Exchange
18.69
CAD
-0.25
- -
22.27BMarket Cap
Sanofi
SNY.TO
(Toronto Stock Exchange)

Recent

price

18.69

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
26.08
26.52
27.25
23.65
24.32
26.69
26.97
28.82
28.61
30.11
29.81
31.28
32.4
33.25
35.39
38.28
40.5
Revenue per Share
4.19
4.27
3.7
2.81
3.34
3.28
3.66
6.7
3.45
2.2
9.81
4.97
6.69
4.31
4.44
6.4
3.28
Basic EPS, GAAP
6.28
5.7
4.97
4.27
4.74
4.71
4.74
4.31
2.86
4.74
4.26
6.77
6.73
5.87
4.7
5.91
9.8
Free Cash Flow per Basic Share
2.4
1.04
2.64
2.75
2.79
2.83
2.92
2.95
3.03
3.07
3.14
3.2
3.33
3.56
3.76
3.91
- -
Dividend per Share
40.5
41.91
42.77
42.97
42.54
44.46
45.24
46.31
47.27
47.1
54.91
54.83
59.31
59.17
61.83
59.1
57
Book Value per Share
6.63
-4.5
-0.68
3.3
1.8
4.95
5.02
3.77
-5.82
-1.57
-0.63
-0.62
2.58
0.25
9.17
3.16
0.74
Tangible Book Value per Share
1,305
1,322
1,320
1,323
1,316
1,306
1,287
1,257
1,247
1,250
1,254
1,252
1,252
1,252
1,251
1,220
1,208
Basic Weighted Avg Shares
34,036
35,058
35,957
31,291
31,999
34,861
34,696
36,221
35,677
37,631
37,369
39,175
40,561
41,618
44,286
46,716
48,919
Sales/Revenue/Turnover
24.94
21.76
21.92
20.32
21.06
20.46
21.69
19.88
17.53
19.07
21.11
23.35
26.94
20.88
20.15
20.54
20.58
Operating Margin (%)
5,129
5,553
4,907
5,095
3,280
4,276
3,301
3,686
4,279
7,445
3,671
3,351
3,108
4,429
3,586
5,678
2,086
Depreciation Expense
5,467
5,646
4,888
3,716
4,390
4,287
4,709
8,416
4,306
2,754
12,294
6,223
8,371
5,400
5,560
7,813
3,958
Net Income, GAAP
23.17
8.37
19.2
16.19
21.46
13.52
23.35
31.13
10.92
4.4
13.12
19.98
19.21
16.27
17.98
16.89
22.14
Effective Tax Rate (%)
16.06
16.1
13.59
11.88
13.72
12.3
13.57
23.24
12.07
7.32
32.9
15.89
20.64
12.98
12.55
16.72
8.09
Profit Margin (%)
15,320
7,274
9,032
9,997
10,405
12,872
15,474
10,925
7,271
8,549
9,358
9,358
10,136
6,463
13,426
2,607
-408
Working Capital
6,695
12,499
10,719
10,414
13,276
13,118
16,815
14,326
22,007
21,118
18,962
18,962
16,761
16,102
13,436
15,715
16,323
LT Debt
53,288
56,363
57,486
57,033
56,268
58,210
57,722
58,239
59,035
59,230
69,031
69,031
75,152
74,353
77,857
71,710
69,567
Total Equity
10.91
10.36
8.75
7.34
7.34
8.36
7.55
6.52
7
8.08
7.72
7.95
9.33
7.62
7.69
8.4
8.38
Return on Invested Capital (%)
9.37
9.13
7.41
5.66
6.64
6.4
7.05
11.43
5.9
3.75
14.31
7.08
9.19
6.24
6.45
8.83
4.82
Return on Capital (%)
10.78
10.33
8.61
6.5
7.77
7.51
8.15
14.56
7.36
4.67
19.25
9.06
11.67
7.26
7.34
10.5
5.69
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
4,614
6,181
7,253
LT Borrowings
14,248
12,298
14,646
LT Finance Leases
1,467
1,542
1,677
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,208
1,198
1,214
Market Capitalization
15,955
16,116
14,569

Working Capital

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
30,952
30,164
31,522
Cash, Cash Equivalents & STI
8,467
5,544
6,350
Accounts Receivable, Net
8,410
- -
8,714
Inventories
10,214
23,503
24,123
Total Current Liabilities
28,345
30,008
31,930
Payables & Accruals
9,045
23,650
24,480
ST Debt
4,614
6,181
7,253
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
-7.9%
Free Cash Flow
5.82%
9.63%
22.53%
Net Income, GAAP
34.32%
-1.37%
40.52%
Sales/Revenue/Turnover
3.01%
4.58%
5.49%
Total Cash Common Dividend
2.62%
3.94%
1.45%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
9,726
11,380
12,977
7,631
44,286
2025
10,606
10,735
13,170
12,205
46,716
2026
11,244
12,300
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.91
- -
2.25
0.4
4.44
2025
1.52
3.24
2.3
-0.66
6.4
2026
1.34
0.29
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
3.76
2025
- -
- -
- -
- -
3.91
2026
- -
- -
- -
- -
- -
Similar Companies
Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd (600671.SS)
Roche Holding AG (RHHBY)
Johnson & Johnson (JNJ.DE)
Organon & Co. (OGN)
Marksans Pharma Limited (MARKSANS.NS)
Daiichi Sankyo Company, Limited (DSKYF)
Business
Sanofi is a global biopharmaceutical company engaged in the research, development, manufacture and commercialization of prescription medicines and vaccines; the company also manages a portfolio of mature medicines through strategic partnerships and divestitures. Founded in 1973 and headquartered in Paris, France, Sanofi operates across Europe, the Americas and other international markets, serving patients, healthcare providers and public health customers. Its core business is organized around specialty care, vaccines and general medicines, with key products including Dupixent, which is used in immunology; advanced oncology and immunology therapies such as Sarclisa and other specialty assets; and a broad vaccine portfolio spanning pediatric, booster and travel immunization programs. The company also develops and commercializes medicines in multiple therapeutic areas and continues to expand its pipeline through internal R&D and external innovation partnerships. In recent strategic activity, Sanofi announced the acquisition of Dynavax, adding a marketed adult hepatitis B vaccine and an early-stage shingles candidate to its pipeline; completed the acquisition of Vicebio; entered new partnering arrangements including exclusive rights to KT501 from Kali Therapeutics, ADEL-Y01 from Adel, and Rovadicitinib from CTTQ; and expanded collaboration with Adagene and Enable Injections to support oncology and subcutaneous delivery innovation. The company has also sharpened its portfolio and organizational focus by discontinuing selected late-stage development programs, executing a €1 billion share buyback, completing a major capital-redeployment program, and reorganizing its executive leadership team to support business development, manufacturing, R&D and geographic priorities.